Отчеты о трансплантации: открытый доступ

Абстрактный

Medicine's Recommendation that All Survivors Admit Treatment Summaries and Personalized Care Plans

Thomas Force

Hematopoietic cell transplantation (HCT) is an important curative treatment for children with high- threat hematologic malignancies, solid tumors, and, decreasingly, nonmalignant conditions. Given advancements in care,there are a growing number of long- term survivors of pediatric HCT. Compared with nonage cancer survivors who didn't suffer transplantation, HCT survivors have a mainly increased burden of serious habitual conditions and impairments involving virtually every organ system and overall quality of life. This probably reflects the common benefactions of pretransplantation treatment exposures and organ dysfunction, the transplantation exertion authority, and any posttransplantation graft- versus- host complaint (GVHD). In response, the Children's Oncology Group (COG) has created long- term follow- up guidelines for survivors of childhood, adolescent, and youthful adult cancer, including those who were treated with HCT [1]. Guideline task forces, conforming of HCT specialists, other pediatric oncologists, radiation oncologists, organ-specific subspecialists, nurses, social workers, other health care professionals, and patient lawyers totally reviewed the literature with respects to late goods after nonage cancer and HCT since 2002, with the most recent review completed in 2013. For the most recent review cycle, over 800 papers from the medical literature applicable to nonage cancer and HCT survivorship were reviewed, including 586 original exploration papers. Handed herein is an organ system – grounded overview that emphasizes the most applicable COG recommendations( with accompanying substantiation grade) for the long- term follow- up care of childhood HCT survivors( anyhow of current age) grounded on a rigorous review of the available substantiation. These recommendations cover both autologous and allogeneic HCT survivors, those who passed transplantation for nonmalignant diseases, and those with a history of habitual GVHD [2].